Biological Prognostic Markers in Chronic Lymphocytic Leukemia

by Vladimíra Vroblová, Lukáš Smolej, Filip Vrbacký, Karolína Jankovičová, Monika Hrudková, Jaroslav Malý, Jan Krejsek
Published 2009-01-01

The significance of enzyme and transporter polymorphisms for imatinib plasma levels and achieving an optimal response in chronic myeloid leukemia patients

by Petra Belohlavkova, Filip Vrbacky, Jaroslava Voglova, Zdenek Racil, Daniela Zackova, Katerina Hrochova, Jana Malakova, Jiri Mayer, Pavel Zak
Published 2018-02-01

CASE 2–2012: a 57-Year-Old Woman with Post-Transplant Lymphoproliferative Disorder after Allogeneic Stem Cell Transplantation for Primary Myelofibrosis

by Milan Košťál, Pavel Žák, Eva Vejražková, Melánie Cermanová, Petra Bělohlávková, Alžběta Zavřelová, Filip Vrbacký, Tomáš Rozkoš, Markéta Nová
Published 2012-01-01

Cervical microbiota in women with preterm prelabor rupture of membranes.

by Marian Kacerovsky, Marian Kacerovsky, Filip Vrbacky, Radka Kutova, Lenka Pliskova, Ctirad Andrys, Ivana Musilova, Ramkumar Menon, Ronald Lamont, Jana Nekvindova
Published 2015-01-01

Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment

by Monika Jaruskova, Nikola Curik, Rajna Hercog, Vaclava Polivkova, Eliska Motlova, Vladimir Benes, Hana Klamova, Pavla Pecherkova, Petra Belohlavkova, Filip Vrbacky, Katerina Machova Polakova
Published 2017-04-01